In an interview on CNBC’s Mad Money, Dr. Albert Bourla said Pfizer (PFE) is focusing on business development to create shareholder value. “We are very happy with the performance of the Nurtec and Seagen assets,” he noted. Bourla does not want to sell the company’s Covid vaccine as he considers it a “great asset.”
Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PFE:
- Senate panel advances Kennedy’s nomination for HHS secretary, CNBC reports
- China retaliates with tariffs on U.S., Merck falls after earnings: Morning Buzz
- Morning Movers: Spotify and Pfizer climb after fourth quarter results
- PFE Earnings: Pfizer Stock Jumps on Q4 Beats
- Pfizer reports Q4 adjusted EPS 63c, consensus 46c